Duration of Levetiracetam (Keppra) Therapy and Tapering
For seizure prophylaxis after intracerebral hemorrhage (ICH), levetiracetam should be discontinued within 7 days if no clinical or electrographic seizures occur, as prophylactic antiseizure medications do not prevent late seizures and may negatively impact cognitive outcomes. 1
Duration Based on Clinical Context
Post-Intracerebral Hemorrhage (ICH)
Discontinue prophylactic levetiracetam within 7 days if the patient remains seizure-free, as meta-analyses demonstrate that seizure prophylaxis does not prevent either early (<14 days) or long-term seizures after spontaneous ICH. 1
Risk scores such as the CAVE score should not be used to guide continuation of antiepileptic drugs beyond 7 days, as there is no evidence that prophylactic medications prevent late seizures (>7 days after ICH). 1
Prophylactic antiseizure drugs may worsen functional outcomes, particularly cognitive function, without providing seizure prevention benefit. 1
Status Epilepticus Treatment
After achieving seizure control with intravenous levetiracetam for status epilepticus, transition to maintenance dosing and continue for at least 6–12 months before considering withdrawal. 2
Maintenance dosing after status epilepticus resolution:
Load with a long-acting anticonvulsant (phenytoin/fosphenytoin, valproate, levetiracetam, or phenobarbital) during any midazolam infusion to ensure adequate levels are established before tapering anesthetic agents. 2
Newly Diagnosed Epilepsy
For patients with newly diagnosed epilepsy who achieve seizure freedom, continue levetiracetam for a minimum of 2 years seizure-free before considering withdrawal. 3
In newly diagnosed epilepsy, 73% of patients achieved 6-month seizure freedom on levetiracetam, with 86% of those maintaining 1-year remission. 3
Most patients (80.1%) who achieved 6-month remission did so at the lowest dose level (1,000 mg daily), suggesting that lack of seizure control requiring continued dose escalation should prompt early consideration of switching medications rather than prolonged high-dose therapy. 3
Post-Stroke Seizures
For late-onset post-stroke seizures (≥2 weeks after ischemic stroke), continue levetiracetam for at least 1–2 years after achieving seizure freedom. 4
- In post-stroke seizure patients, 77.1% achieved 1-year seizure freedom: 54.3% at 1,000 mg daily, 20% at 1,500 mg daily, and 2.8% at 2,000 mg daily. 4
Tapering Schedule
When discontinuing levetiracetam after an appropriate seizure-free period, taper by 250–500 mg every 1–2 weeks while maintaining continuous EEG monitoring if the patient had refractory status epilepticus. 2
Critical Monitoring During Taper
Continuous EEG monitoring should be maintained throughout the entire tapering process and for at least 24–48 hours after discontinuation in patients who had refractory status epilepticus, as breakthrough seizures occur in more than 50% of patients and are often only detectable by EEG without clinical manifestations. 2
Avoid attributing altered mental status solely to post-ictal state or sedation—obtain urgent EEG if the patient does not awaken within the expected timeframe, as nonconvulsive status epilepticus occurs in >50% of cases. 2
Common Pitfalls to Avoid
Do not continue prophylactic levetiracetam beyond 7 days after ICH in seizure-free patients, as this provides no benefit and may cause cognitive harm. 1
Do not use risk stratification scores to justify prolonged prophylaxis after ICH, as they do not predict which patients will benefit from continued antiseizure medications. 1
Do not abruptly discontinue levetiracetam after status epilepticus without loading a long-acting maintenance anticonvulsant, as this leads to seizure recurrence. 2
In patients with refractory epilepsy on long-term therapy, ensure compliance before escalating treatment, as non-compliance is a common cause of breakthrough seizures. 2